Moderna Inc (Extended Hours)

No trades

See on Supercharts

Overview

News Ideas Discussions Seasonals

MRNA chart

Full chart

Key facts today

Moderna's shares fell 38% this year, now at $26, near pre-Covid vaccine approval levels. Its market value is about $9.9 billion, just above $9.5 billion in cash and investments.

Moderna, in collaboration with GSK and Pfizer, has received U.S. Food and Drug Administration approval for its RSV vaccines, entering a competitive market where GSK's Arexvy currently leads in sales.

Analyze the impact Analyze the impact